Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary EndpointGlobeNewsWire • 12/01/20
Are Options Traders Betting on a Big Move in Ovid Therapeutics (OVID) Stock?Zacks Investment Research • 11/25/20
Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual CongressGlobeNewsWire • 11/23/20
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/12/20
Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development ProgramGlobeNewsWire • 10/14/20
Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual CongressGlobeNewsWire • 10/12/20
Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare EpilepsiesGlobeNewsWire • 09/30/20
Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare ConferenceGlobeNewsWire • 09/11/20
Ovid Therapeutics: Strong Buy After Fall On Necessary Dilution Backed By Positive DataSeeking Alpha • 08/28/20
Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut SyndromeGlobeNewsWire • 08/25/20
Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/10/20
Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020GlobeNewsWire • 08/05/20
Ovid Therapeutics Is Quickly Approaching A Transformational Valuation MilestoneSeeking Alpha • 08/05/20
Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman SyndromeGlobeNewsWire • 07/23/20
Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in EuropeGlobeNewsWire • 07/13/20
Implied Volatility Surging for Ovid Therapeutics (OVID) Stock OptionsZacks Investment Research • 06/22/20
Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman SyndromeGlobeNewsWire • 06/19/20